dulaglutide
Marketed as TRULICITY.
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA125469 | TRULICITY | 2014-09-18 | ELI LILLY AND CO |
Manufacturers
ELI LILLY AND CO
Common denial patterns
- Step therapy requiring semaglutide or tirzepatide first (clinically-preferred per ADA 2024)
- Non-formulary tier 4 specialty
- Quantity limit on weekly pen
- Prior auth requiring A1C ≥7.5% documentation
Specific notes
Brand: Trulicity. Once-weekly GLP-1 for T2D. REWIND trial established CV risk reduction in T2D with or without established CV disease. Often displaced as plans prefer semaglutide or tirzepatide.
Lilly Cares Foundation: https://www.lillycares.com
Frequently asked questions
Why does insurance commonly deny dulaglutide?
Step therapy requiring semaglutide or tirzepatide first (clinically-preferred per ADA 2024); Non-formulary tier 4 specialty; Quantity limit on weekly pen; Prior auth requiring A1C ≥7.5% documentation.
When was dulaglutide FDA approved?
Earliest FDA approval on record: 2014-09-18.
What brand names are sold as dulaglutide?
TRULICITY.
Is there a patient assistance program for dulaglutide?
Yes — Lilly Cares Foundation at https://www.lillycares.com.
What's specific to dulaglutide?
Brand: Trulicity. Once-weekly GLP-1 for T2D. REWIND trial established CV risk reduction in T2D with or without established CV disease. Often displaced as plans prefer semaglutide or tirzepatide.
Related
Sources
Appeal a dulaglutide denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com